Status:
COMPLETED
Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy
Lead Sponsor:
AstraZeneca
Conditions:
Cardiovascular Prevention
Eligibility:
All Genders
50-84 years
Brief Summary
This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are: To estimate the one year risk of discontinuation of use of low-dose ...
Detailed Description
Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention
Eligibility Criteria
Inclusion
- Patients aged 50-84 years in 2000-2007.
- Patients with first prescription of low dose ASA ( see study population description).
- Patients were required to have been enrolled with their primary care practitioner (PCP) for at least 2 years and to have a computerized prescription history of at least 1 year before the start of the study.
Exclusion
- Patients aged below age 50 and 85 years and above ( see study population description).
- Patients with a diagnosis of cancer, alcohol abuse or alcohol-related disease.
- Incomplete data recording in THIN.
Key Trial Info
Start Date :
September 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
35604 Patients enrolled
Trial Details
Trial ID
NCT01888575
Start Date
September 1 2012
End Date
June 1 2013
Last Update
May 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Madrid, Spain